Table 2 Cumulative incidence and hazard ratio of Parkinson disease between groups.
From: Association of nucleos(t)ide analogue therapy with Parkinson disease in chronic hepatitis B patients
Year | NUC Treatment group | Multiple competing risk model* | Multiple competing risk model** | Propensity score-matched model | |||
|---|---|---|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | ||
1 | NUC (−) | 1.00 | 0.0584 | 1.00 | 0.1081 | 1.00 | 0.1772 |
NUC (+) | 0.38 (0.14–1.04) | 0.44 (0.16–1.20) | 0.45 (0.14–1.44) | ||||
2 | NUC (−) | 1.00 | 0.0530 | 1.00 | 0.1105 | 1.00 | 0.0412 |
NUC (+) | 0.58 (0.33–1.01) | 0.63 (0.36–1.11) | 0.50 (0.26–0.97) | ||||
3 | NUC (−) | 1.00 | 0.0139 | 1.00 | 0.0379 | 1.00 | 0.0349 |
NUC (+) | 0.57 (0.37–0.89) | 0.61 (0.39–0.97) | 0.56 (0.32–0.96) | ||||
4 | NUC (−) | 1.00 | 0.0282 | 1.00 | 0.0997 | 1.00 | 0.0147 |
NUC (+) | 0.67 (0.47–0.96) | 0.73 (0.51–1.06) | 0.58 (0.38–0.90) | ||||
5 | NUC (−) | 1.00 | 0.2546 | 1.00 | 0.4126 | 1.00 | 0.1192 |
NUC (+) | 0.85 (0.64–1.13) | 0.89 (0.66–1.19) | 0.75 (0.52–1.08) | ||||
6 | NUC (−) | 1.00 | 0.4722 | 1.00 | 0.8842 | 1.00 | 0.1960 |
NUC (+) | 0.92 (0.72–1.17) | 0.98 (0.76–1.26) | 0.81 (0.59–1.11) | ||||
7 | NUC (−) | 1.00 | 0.6101 | 1.00 | 0.9020 | 1.00 | 0.3712 |
NUC (+) | 0.95 (0.76–1.18) | 1.01 (0.81–1.27) | 0.88 (0.65–1.17) | ||||
